ProPhase Labs, Inc. (NASDAQ:PRPH) Q1 2023 Results Conference Call May 11, 2023 11:00 AM ET Company Participants Ted Karkus - CEO and Chairman Conference Call Participants Hunter Diamond - Diamond Equity Research Yi Chen - H.C. Wainwright Operator Good day, and welcome to the ProPhase Labs Inc. First Quarter 2023 Financial Results and Corporate Update Conference Call. All participants will be in listen only mode [Operator Instructions]. Please note this event is being recorded. I would now like to turn the ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ to ______ Commission file number 000-21617 ProPhase Labs, Inc. (Exact name of registrant as specified in its charter) Delaware 23-2577138 ...

ProPhase Labs, Inc. (NASDAQ:PRPH) Q4 2022 Earnings Conference Call March 28, 2023 11:00 AM ET Company Participants Ted Karkus - Chairman and Chief Executive Officer Conference Call Participants Yi Chen - H.C. Wainwright Hunter Diamond - Diamond Equity Research Patrick Patterson - Private Investor Fred McDonald - Private Investor Operator Hello and welcome to the ProPhase Labs Financial Results for the Year Ended December 31, 2022 Conference Call. [Operator Instructions] Please note this event is being recor ...

ProPhase Labs, Inc. (NASDAQ:PRPH) Q3 2022 Earnings Conference Call November 10, 2022 11:00 AM ET Company Participants Ted Karkus – Chairman and Chief Executive Officer Conference Call Participants Fred McDonald – Private Investor Yi Chen – H.C. Wainwright Dennis Waldman – Barrett Productions, LLC Patrick Patterson – Investor Operator Good morning, afternoon, evening, and welcome to the ProPhase Labs Third Quarter 2022 Financial Results Conference Call. All participants will be in listen-only mode. [Operator ...

Financial Performance - For the three months ended September 30, 2022, net revenue was $24.2 million, a significant increase from $9.5 million for the same period in 2021, driven by a $13.4 million increase in diagnostic services revenue [225]. - For the nine months ended September 30, 2022, net revenue reached $100.8 million, up from $33.9 million in the same period in 2021, primarily due to a $64.2 million increase in diagnostic services revenue [235]. - Net income for the three months ended September 30, 2022, was $1.0 million, or $0.06 per share, compared to a net loss of $4.0 million, or ($0.26) per share, in Q3 2021 [234]. - Net income for the nine months ended September 30, 2022, was $20.9 million, or $1.33 per share, compared to a net loss of $4.3 million, or ($0.29) per share, in 2021 [243]. - Adjusted EBITDA for the nine months ended September 30, 2022, was $35.5 million, compared to $1.6 million in 2021 [248]. Revenue and Testing Volume - Overall diagnostic testing volume increased from 62,000 tests in Q3 2021 to 113,000 tests in Q3 2022, with 49.4% of tests reimbursed by the HRSA uninsured program [225]. - Approximately 31.5% of diagnostic services revenue for the nine months ended September 30, 2022, was generated from the HRSA program for uninsured individuals, down from 64.7% in 2021 [256]. Cost and Expenses - Cost of revenues for the nine months ended September 30, 2022, was $41.5 million, compared to $16.5 million for the same period in 2021, with diagnostic services accounting for $33.6 million of the total [236]. - General and administration expenses for Q3 2022 were $7.5 million, an increase from $5.9 million in Q3 2021, primarily due to higher personnel expenses and professional fees [230]. - General and administration expenses rose to $21.6 million in 2022 from $14.7 million in 2021, primarily due to higher personnel expenses and professional fees [239]. - Research and development costs decreased to $110,000 in Q3 2022 from $208,000 in Q3 2021, reflecting reduced personnel expenses [231]. - Research and development costs decreased to $0.2 million in 2022 from $0.4 million in 2021, mainly due to reduced personnel expenses [240]. - Interest expense decreased to $0.6 million in 2022 from $0.9 million in 2021, attributed to the repayment of convertible notes [242]. Profitability and Margins - Gross profit for the three months ended September 30, 2022, was $12.0 million, compared to $4.0 million in Q3 2021, resulting in a gross margin of 49.5% versus 42.0% in the prior year [228]. - Gross profit for the nine months ended September 30, 2022, was $59.4 million, up from $17.4 million in the same period of 2021, reflecting a gross margin increase from 51.2% to 58.9% [237]. - Diagnostic services gross margin improved to 63.4% in 2022 from 56.8% in 2021, driven by increased efficiencies and reduced costs [237]. Cash and Liquidity - Cash, cash equivalents, and restricted cash increased to $22.8 million as of September 30, 2022, from $8.7 million at December 31, 2021, with working capital rising to $53.6 million [251]. - The company estimates sufficient cash and liquidity to finance operations for at least 12 months, despite uncertainties in the diagnostic testing business beyond COVID-19 [252]. Accounting and Risk Management - The company evaluates accounts receivable and establishes an allowance for doubtful accounts based on past write-offs and current credit conditions [267]. - Goodwill and long-lived assets are reviewed annually for impairment, with fair value determined by market prices or projected future cash flows [269]. - The Tax Cuts and Jobs Act reduced the federal tax rate from 35% to 21%, effective January 1, 2018, impacting deferred tax assets and liabilities [270]. - Inventory is valued at the lower of cost or net realizable value, with provisions for excess and obsolete inventory based on customer demand [272]. - The adoption of ASU 2020-06 did not have a material impact on the company's financial statements or disclosures [273]. - The company is assessing the impact of ASU 2016-13, which introduces a current expected credit loss model effective for fiscal years beginning after December 15, 2022 [275]. - Current economic conditions may lead to a decline in business and consumer spending, adversely affecting accounts receivables and asset recoverability [279]. - There have been no material changes to market risk exposures since December 31, 2021, except for the effects of COVID-19 on the global economy [280]. Strategic Initiatives - The company continues to pursue acquisition opportunities for technologies and products within and outside the consumer products industry [223].

NOVEMBER 2022 A ProPhase | --- | --- | --- | --- | |-------|-------|-------|-------------------------| | | | | ProPhaseLabs.com | | | | | CORPORATE PRESENTATION | | | | | NASDAQ: PRPH | FORWARD LOOKING STATEMENTS This presentation contains forward‐looking statements relating to our strategy and business objectives. All statements other than statements of historical facts included in this presentation may be deemed to be forward‐looking statements including statements regarding our strategy, plans, objective ...

SEPTEMBER 2022 ▲ ProPhase | --- | --- | --- | --- | |-------|-------|-------|------------------------------------------| | | | | | | | | | ProPhaseLabs.com CORPORATE PRESENTATION | | | | | | | | | | NASDAQ: PRPH | FORWARD LOOKING STATEMENTS This presentation contains forward‐looking statements relating to our strategy and business objectives. All statements other than statements of historical facts included in this presentation may be deemed to be forward‐looking statements including statements regarding ou ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____to _____ Commission file number 000-21617 ProPhase Labs, Inc. (Exact name of registrant as specified in its charter) Delaware 23-2577138 (State or other jurisdiction ...

ProPhase Labs, Inc (NASDAQ:PRPH) Q2 2022 Earnings Conference Call August 11, 2022 9:00 AM ET Company Participants Ted Karkus - Chairman & Chief Executive Officer Conference Call Participants Yi Chen - H.C. Wainwright Dennis Waldman - Barrett Productions, LLC Operator Good morning, and welcome to the ProPhase Labs Second Quarter 2022 Financial Results and Corporate Update. [Operator Instructions] Please note this is event is being recorded. I would now like to conference over to Ted Karkus, CEO and Chairman ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____to _____ Commission file number 000-21617 ProPhase Labs, Inc. (Exact name of registrant as specified in its charter) Delaware 23-2577138 (State or other jurisdictio ...